Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 428

1.

Efficacy of solifenacin in patients with severe symptoms of overactive bladder: a pooled analysis.

Millard RJ, Halaska M.

Curr Med Res Opin. 2006 Jan;22(1):41-8.

PMID:
16393429
2.

Efficacy and tolerability of solifenacin in elderly subjects with overactive bladder syndrome: a pooled analysis.

Wagg A, Wyndaele JJ, Sieber P.

Am J Geriatr Pharmacother. 2006 Mar;4(1):14-24.

PMID:
16730617
3.
4.

Randomized, double-blind, placebo- and propiverine-controlled trial of the once-daily antimuscarinic agent solifenacin in Japanese patients with overactive bladder.

Yamaguchi O, Marui E, Kakizaki H, Itoh N, Yokota T, Okada H, Ishizuka O, Ozono S, Gotoh M, Sugiyama T, Seki N, Yoshida M; Japanese Solifenacin Study Group..

BJU Int. 2007 Sep;100(3):579-87.

5.

Randomized, double-blind placebo- and tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder.

Chapple CR, Rechberger T, Al-Shukri S, Meffan P, Everaert K, Huang M, Ridder A; YM-905 Study Group..

BJU Int. 2004 Feb;93(3):303-10.

PMID:
14764127
6.

Solifenacin in the treatment of urgency and other symptoms of overactive bladder: results from a randomized, double-blind, placebo-controlled, rising-dose trial.

Cardozo L, Hessdörfer E, Milani R, Arañó P, Dewilde L, Slack M, Drogendijk T, Wright M, Bolodeoku J; SUNRISE Study Group..

BJU Int. 2008 Nov;102(9):1120-7. doi: 10.1111/j.1464-410X.2008.07939.x.

8.
9.

Treatment with solifenacin increases warning time and improves symptoms of overactive bladder: results from VENUS, a randomized, double-blind, placebo-controlled trial.

Karram MM, Toglia MR, Serels SR, Andoh M, Fakhoury A, Forero-Schwanhaeuser S.

Urology. 2009 Jan;73(1):14-8. doi: 10.1016/j.urology.2008.08.485.

PMID:
18995887
10.
11.

Redefining response in overactive bladder syndrome.

Payne CK, Kelleher C.

BJU Int. 2007 Jan;99(1):101-6. Review.

12.

Randomized, double-blind placebo controlled trial of the once daily antimuscarinic agent solifenacin succinate in patients with overactive bladder.

Cardozo L, Lisec M, Millard R, van Vierssen Trip O, Kuzmin I, Drogendijk TE, Huang M, Ridder AM.

J Urol. 2004 Nov;172(5 Pt 1):1919-24.

PMID:
15540755
13.

Solifenacin for overactive bladder with incontinence: symptom bother and health-related quality of life outcomes.

Garely AD, Lucente V, Vapnek J, Smith N.

Ann Pharmacother. 2007 Mar;41(3):391-8.

PMID:
17341526
14.

Reductions in overactive bladder-related incontinence from pooled analysis of phase III trials evaluating treatment with solifenacin.

Cardozo L, Castro-Diaz D, Gittelman M, Ridder A, Huang M.

Int Urogynecol J Pelvic Floor Dysfunct. 2006 Sep;17(5):512-9.

PMID:
16625311
15.

Solifenacin significantly improves all symptoms of overactive bladder syndrome.

Chapple CR, Cardozo L, Steers WD, Govier FE.

Int J Clin Pract. 2006 Aug;60(8):959-66. Review. Erratum in: Int J Clin Pract. 2006 Nov;60(11):1517-8.

16.

Impact of solifenacin on diary-recorded and patient-reported urgency in patients with severe overactive bladder (OAB) symptoms.

Serels SR, Toglia MR, Forero-Schwanhaeuser S, He W.

Curr Med Res Opin. 2010 Oct;26(10):2277-85. doi: 10.1185/03007995.2010.509582.

PMID:
20707767
17.

Efficacy of solifenacin in patients previously treated with tolterodine extended release 4 mg: results of a 12-week, multicenter, open-label, flexible-dose study.

Chancellor MB, Zinner N, Whitmore K, Kobashi K, Snyder JA, Siami P, Karram M, Laramée C, Capo' JP Jr, Seifeldin R, Forero-Schwanhaeuser S, Nandy I.

Clin Ther. 2008 Oct;30(10):1766-81. doi: 10.1016/j.clinthera.2008.10.011.

PMID:
19014833
18.

Improved quality of life in patients with overactive bladder symptoms treated with solifenacin.

Kelleher CJ, Cardozo L, Chapple CR, Haab F, Ridder AM.

BJU Int. 2005 Jan;95(1):81-5.

19.

Solifenacin succinate for the treatment of symptoms of overactive bladder.

Maniscalco M, Singh-Franco D, Wolowich WR, Torres-Colón R.

Clin Ther. 2006 Sep;28(9):1247-72. Review.

PMID:
17062299
20.

Long-term open-label solifenacin treatment associated with persistence with therapy in patients with overactive bladder syndrome.

Haab F, Cardozo L, Chapple C, Ridder AM; Solifenacin Study Group..

Eur Urol. 2005 Mar;47(3):376-84.

PMID:
15716204
Items per page

Supplemental Content

Support Center